Voyageur Pharmaceuticals ( (TSE:VM) ) has issued an update.
Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for ...
Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is excited to ...
Two medical ultrasound organizations today announced their endorsement of expanded training in Contrast Enhanced Ultrasound (CEUS) under the newly updated National Education Curriculum (NEC) for ...
Contrast media used for medical imaging may be contributing to environmental pollution as researchers measure and consider the impact.
The administration of iodinated contrast media (ICM) between January 2014 and November 2024 in the US resulted in anaphylaxis at a rate of 20.3 cases per 100,000 scans, 13% of which were ...
Hosted on MSN
Contrast Dye in Medical Imaging Dangers
Disclaimer: Important, this article is for general information only and is not medical advice. Please speak to your clinician about your personal risks and benefits. If you experience symptoms after ...
CHICAGO--(BUSINESS WIRE)--The International Contrast Ultrasound Society (ICUS) today urged the Centers for Medicare and Medicaid Services (CMS) to update reimbursement for certain contrast-enhanced ...
Calgary, Alberta, Canada –TheNewswire -June 4, 2025 - Voyageur Pharmaceuticals Ltd. (VM:CA) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on vertical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback